Breaking News

GVK BIO Completes Drug Repurposing Efforts for Takeda

To develop new indications for shelved compounds

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GVK Biosciences has successfully completed in-silico based alternative indications of shelved compounds for Takeda Pharmaceutical Co. Ltd. using its Drug Repurposing Platform. GVK BIO and Takeda have jointly agreed to evaluate the preclinical proof-of-concept for certain indications of selected therapeutic compounds to develop new indications for the previously failed compounds.   GVK BIO’s Drug Repurposing Platform, GRIP (GVK BIO Repurposing Integrated Platform), is a combination of proprietary...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters